Kiniksa Pharmaceuticals Provides Corporate Update

Core Insights - Kiniksa Pharmaceuticals reported a net product revenue of $677.5 million for ARCALYST in 2025, marking a 62% year-over-year growth, with expectations for 2026 revenue between $900 million and $920 million [1][6][2] Financial Performance - The gross-to-net ratio for ARCALYST was 8.4% in 2025, down from 9.8% in 2024, influenced by the Inflation Reduction Act and prior period reserve adjustments [6] - Kiniksa's cash balance increased by $170.4 million in 2025, totaling $414.1 million with no debt [1][7] Product Development - KPL-387 is in Phase 2 clinical trials for recurrent pericarditis, with data expected in the second half of 2026 [1][6][2] - KPL-1161, an Fc-modified monoclonal antibody, is set to enter Phase 1 trials by the end of 2026 [1][4][2] Market Position - As of the end of 2025, approximately 18% of the 14,000 multiple-recurrence patients were on ARCALYST therapy, indicating a growing market presence [6][2] - The average duration of ARCALYST therapy in recurrent pericarditis is approaching 3 years, aligning with the median duration of the disease [6]